Natera, Inc. R&D increased by 20.3% to $210.70M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 63.2%, from $129.08M to $210.70M. Over 4 years (FY 2021 to FY 2025), R&D shows an upward trend with a 24.0% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $53.75M | $98.46M | $71.81M | $80.41M | $82.58M | $65.51M | $87.91M | $82.31M | $78.17M | $77.24M | $82.96M | $88.64M | $89.11M | $96.93M | $129.46M | $129.08M | $146.43M | $173.41M | $175.19M | $210.70M |
| QoQ Change | — | +83.2% | -27.1% | +12.0% | +2.7% | -20.7% | +34.2% | -6.4% | -5.0% | -1.2% | +7.4% | +6.8% | +0.5% | +8.8% | +33.6% | -0.3% | +13.4% | +18.4% | +1.0% | +20.3% |
| YoY Change | — | — | — | — | +53.6% | -33.5% | +22.4% | +2.4% | -5.3% | +17.9% | -5.6% | +7.7% | +14.0% | +25.5% | +56.0% | +45.6% | +64.3% | +78.9% | +35.3% | +63.2% |